EHA 2025 – Arcellx still hopes safety will trump efficacy

More data from the registrational Immagine-1 trial of Arcellx and Gilead’s anitocabtagene autoleucel in late-line multiple myeloma, presented at EHA on Saturday, continue to suggest that this project has similar efficacy to Legend and Johnson & Johnson’s Carvykti, but with better safety. At the latest cut anito-cel produced a 97% ORR, but notably has still not been linked with delayed neurotoxicity, such as Parkinsonism. Arcellx and Gilead will have to hope that this is enough to gain market share in the BCMA Car-T space. At an investor event on Friday Arcellx pushed its claims of best-in-class potential, disclosing findings from a physician survey in which 83% of 152 doctors said they would prefer anito-cel over similarly acting products. Arcellx will need this apparent interest to translate into real sales when it launches anito-cel, slated for mid to late 2026, although the company has been coy about its filing timeline. Arcellx reckons anito-cel will help expand the multiple myeloma Car-T market to $12bn in 2028 and beyond – echoing comments from last year’s ASH meeting that there’s plenty of pie to go around. Carvykti, meanwhile, sold $963m in 2024.

Car-T cross-trial comparison in 4th-line-plus multiple myeloma

Note: *figure cited by Arcellx in EHA 2025 presentation. Source: EHA 2025 & Carvykti label.